Takeda's post-transplant CMV drug Livtencity, shouldering $800M in sales expectations, scores FDA nod

24th November 2021 Uncategorised 0

Takeda’s post-transplant CMV drug Livtencity, shouldering $800M in sales expectations, scores FDA nod
aliu
Wed, 11/24/2021 – 10:19

More: Takeda's post-transplant CMV drug Livtencity, shouldering 0M in sales expectations, scores FDA nod
Source: fierce